Cardinal Health, Inc.

Strong Financial Performance: Cardinal Health reported Q2 FY2025 earnings per share (EPS) of $1.93, a 2% increase year-over-year, and raised fiscal year EPS guidance to a range of $7.85 to $8. This reflects robust growth in the Pharmaceutical and Specialty Solutions segment, which saw a 17% revenue increase when adjusted for customer contract expirations.

Pharmaceutical and Specialty Growth Driven by Strategic Actions: The company’s Pharmaceutical segment generated $51 billion in revenue, with a 7% profit increase driven by brand and specialty sales, including a 6.5 percentage point contribution from GLP-1 drugs. The integration of new acquisitions (GI Alliance and Integrated Oncology Network) is expected to contribute positively moving forward.

GMPD Challenges and Profit Outlook: The GMPD segment experienced softer revenue growth (1% increase) and challenges related to respiratory products, resulting in a revision of segment profit guidance to $130 million to $150 million. This included a $15 million write-off from WaveMark due to uncollectible receivables and highlights the ongoing operational struggles within this segment.